Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/517,781
Filing Date	April 20, 2005
First Named Inventor	KAHN, Saeed R.
Art Unit	1621
Examiner Name	NWAONICHA, Chukwuma O.
Attorney Docket Number	018890-000810US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5814622	9/29/1998	de Nanteuil et al.	
	AB	US-6083903	7/4/2000	Adams et al.	
	AC	US-6297217 B1	10/2/2001	Adams et al.	
	AD	US-5808137	9/15/1998	Bombardelli et al.	
	AE	US-6147082	11/14/2000	Bombardelli et al.	
	AF	US-6423740 B1	7/23/2002	Bombardelli et al.	
	AG	US-6462075 B1	10/8/2002	Bowen et al.	
	AH	US-5808137	9/15/1998	Bombardelli et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AI	PCT	96/19209	A1	6/27/1996	Indena S.P.A.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AJ	BAKER et al., Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, 1990, 249:912-5	
	AK	BODOR, Nicholas, Targeting of drugs to the brain, Methods in Enzymology, 112:381-96, 1985	
	AL	BOYD et al., A novel cellular protein (MTBP) binds to MDM2 and induces a G_1 arrest that is suppressed by MDM2*, J. Biol. Chem., 2000, 275(41):31883-90	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/517,781
				Filing Date	April 20, 2005
				First Named Inventor	KAHN, Saeed R.
				Art Unit	1621
(Use as many sheets as necessary)				Examiner Name	NWAONICHA, Chukwuma O.
Sheet	2	of	5	Attorney Docket Number	018890-000810US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	AM	BUNDGAARD, H., Means to enhance penetration, prodrugs as a means to improve the delivery of peptide drugs, Advanced Drug Delivery Reviews, 8:1-38, 1992	
	AN	BUNDGAARD, Hans, Formation of prodrugs of amines, amides, ureides, and imides, Methods in Enzymology, 112:347-59, 1985	
	AO	CALLISTE et al., Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities, Anticancer Res., 2001, 21:3949-56	
	AP	DE VINCENZO et al., Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships, Anticancer Drug Des., 1995, 10:481-90	
	AQ	DICESARE et al., Chalcone-analogue fluorescent prfobes for saccharides signaling using the boronic acid group, Tetrahedron Letters 43:2615-8, 2002	☐
	AR	DICESARE et al., New sensitive and selective fluorescent probes for fluoride using boronic acids, Analytical Biochemistry 301:111-6, 2002	☐
	AS	DILLER et al., p53 Functions as a cell cycle control protein in osteosarcomas, Mol. Cell. Biol., 1990, 10(11):5772-81	
	AT	FAKHARZADEH et al., Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line, EMBO J., 1991, 10(6):1565-9	
	AU	FLEISHER et al., Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting, Methods in Enzymology, 112:360-81, 1985	
	AV	JUVEN-GERSHON et al., MDM2: The ups and downs, Mol. Med. 1999, 5:71-83	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known	
Application Number	10/517,781
Filing Date	April 20, 2005
First Named Inventor	KAHN, Saeed R.
Art Unit	1621
Examiner Name	NWAONICHA, Chukwuma O.
Attorney Docket Number	018890-000810US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	AW	KAKEYA et al., Studies of prodrugs of cephalosporins. I. [1)] Synthesis and biological properties of glycyloxybenzoyloxymethyl and glycylaminobenzoyloxymethyl esters of 7β-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-methyl-3-cephem-4-carboxylic acid, Chem. Pharm. Bull. 32:692-8, 1984	
	AX	KROGSGAARD-LARSEN et al., Design and application of prodrug, A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chap. 5:113-91, 1991	
	AY	KUMAR et al., Design, Synthesis and evaluation of novel boronic-chalcone derivatives as antitumor agents, J. of Med. Chem., 46:2813-5, 2003	☐
	AZ	LANE et al., MDM2-arbiter of p53's destruction, Trends Biochem. Sci., 1997, 22:372-4	
	BA	LOZANO et al., MDM2 function, Biochem. Biophys. Acta, 1998, 1377:M55-M59	
	BB	LUNDGREN et al., Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53, Genes Dev., 1997, 11:714-25	
	BC	MAGGIOLINI et al., Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells, J. Steroid Biochem. Mol. Biol. 2002, 82:315-22	
	BD	MAKITA et al., Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin[1], Cancer Res., 1996, 56:4904-9	
	BE	MOMAND et al., The MDM2 gene amplification database, Nucleic Acids Res., 1998, 26(15):3453-9	
	BF	MOSMANN, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 1983, 65:55-63	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 5

Complete if Known	
Application Number	10/517,781
Filing Date	April 20, 2005
First Named Inventor	KAHN, Saeed R.
Art Unit	1621
Examiner Name	NWAONICHA, Chukwuma O.
Attorney Docket Number	018890-000810US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	BG	NELSON, Sidney D., Alteration of drug metabolism by the use of prodrugs, Methods in Enzymology, 112:340-7, 1985	
	BH	NIELSEN et al., Glycolamide esters as biolabile prodrugs of carboxylic acid agents: synthesis, stability, bioconversion, and physicochemical properties, Journal of Pharmaceutical Sciences, 77(4):285-98, 1988	
	BI	NOTARI, Robert E., Theory and Practice of prodrug kinetics, Methods in Enzymology, 112:309-23, 1985	
	BJ	OLINER et al., Amplification of a gene encoding a p53-associated protein in human sarcomas, Nature, 1992, 358:80-3	
	BK	RUI, H., Research and development of cancer chemopreventive agents in China, J. Cell. Biochem. Supp., 1997, 27:7-11	
	BL	SATOMI, Y., Inhibitory effects of 3'-methyl-3-hydroxy-chalcone on proliferation of human malignant tumor cells and on skin carcinogenesis, Int. J. Cancer, 1993, 55:506-14	
	BM	SCHILSKY et al., Infertility and carcinogenesis: late complications of chemotherapy, in Cancer Chemotherapy Principal and Practice, CHABNER et al., Chapter 3:32-58, Lippincott Williams & Wilkins Publishers: Philadelphia, 1990	
	BN	STOLL et al., Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53, Biochemistry, 2001, 40:336-44	
	BO	SWAIN et al., Endocrine therapies of cancer, in Cancer Chemotherapy Principal and Practice, CHABNER et al., Chapter 4:59-109, Lippincott Williams & Wilkins Publishers: Philadelphia, 1990	
	BP	WANG et al., Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: *in vitro* and *in vivo* activities and mechanisms[1], Clinical Cancer Res., 2001, 7:3613-24	
	BQ	WASYLYK et al., p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53, Oncogene, 1999, 18:1921-34	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/517,781
				Filing Date	April 20, 2005
				First Named Inventor	KAHN, Saeed R.
				Art Unit	1621
(Use as many sheets as necessary)				Examiner Name	NWAONICHA, Chukwuma O.
Sheet	5	of	5	Attorney Docket Number	018890-000810US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	BR	WATTENBERG et al., Inhibition of carcinogen-induced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure, Cancer Lett., 1994, 83:165-9	
	BS	YAMAMOTO et al., The potent anti-tumor-promoting agent isoliquiritigenin, Carcinogenesis, 1991, 12(2):317-23	
	BT	ZHANG et al., MDM2 oncogene as a novel target for human cancer therapy, Curr. Pharm. Des., 2000, 6:393-416	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.